PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Etoricoxib→

Etoricoxib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
202409-33-4
Molecular formula
C18H15ClN2O2S
Molecular weight
358.8 g/mol
Drug class
Selective cyclo-oxygenase-2 (COX-2) inhibitorcoxib NSAID
Mechanism of action
Selectively and dose-dependently inhibits COX-2 within the clinical dose range, reducing prostaglandin synthesis associated with pain and inflammation; it does not inhibit COX-1 at doses up to 150 mg daily in cited clinical pharmacology studies.
Indications / reported uses
  • Symptomatic relief of osteoarthritis and rheumatoid arthritis
  • Ankylosing spondylitis
  • Pain and signs of inflammation associated with acute gouty arthritis
  • Short-term treatment of moderate pain associated with dental surgery; age and dose restrictions are product-specific

Sources: UK SmPC — Etoricoxib 30 mg · UK SmPC — Etoricoxib 120 mg · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Etoricoxib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Etoricoxib Permitted Daily Exposure (PDE) report (the Etoricoxib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Etoricoxib Occupational Exposure Limit (OEL) report (the Etoricoxib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.